Entera Bio Ltd. filings document a Nasdaq-listed Israeli clinical-stage biopharmaceutical company developing oral peptide and protein replacement therapies. Its recent Form 8-K disclosures cover financial results, Regulation FD updates, EB613 regulatory and clinical-development communications, and business updates across oral peptide programs.
The filing record also documents material agreements and capital structure matters, including collaboration and license arrangements with OPKO, a private placement involving ordinary shares, pre-funded warrants and ordinary share warrants, and governance disclosures related to board appointments. These filings frame ENTX's operating updates, securities structure, partnership obligations and public-company governance.
Entera Bio Ltd. reported that director Steven D. Rubin received equity compensation consisting of 19,117 ordinary shares granted in lieu of cash director fees for the first two quarters of 2026 and two stock option awards for 33,368 and 43,405 shares at an exercise price of 1.37 per share. The options, expiring on May 7, 2036, were approved after shareholder authorization and a Form S-8 registration and vest over one- and three-year schedules beginning February 1, 2026, with full acceleration upon a Change in Control. Following the share grant, Rubin directly owns 34,117 ordinary shares.
Malca Yonatan reported acquisition or exercise transactions in this Form 4 filing.
Entera Bio Ltd. reported that director Yonatan Malca received a grant of 22,815 Ordinary Shares on August 7, 2026. The award, priced at $0.0000 per share, was issued in lieu of cash fees for serving as director for the first and second quarters of 2026. Following this grant, Malca directly holds 100,231 Ordinary Shares. The Board approved the grant on August 5, 2026, subject to effectiveness of a Registration Statement on Form S-8, which occurred on August 7, 2026.
Taitel Haya reported acquisition or exercise transactions in this Form 4 filing.
Entera Bio Ltd. reported that director Haya Taitel received a board-approved grant of 20,790 ordinary shares on August 7, 2026. The shares were awarded in lieu of cash director fees for the first and second quarters of 2026, after the company filed a Form S-8 registering them. Following this compensation grant, Taitel directly holds 119,269 ordinary shares; the grant carried a reported price of $0.00 per share.
Entera Bio Ltd. director Sean Ellis reported equity compensation awards. He received 20,034 ordinary shares in lieu of cash board fees for the first and second quarters of 2026, after Board approval and a Form S-8 filed on August 7, 2026. He was also granted fully vested options for 40,000 ordinary shares at an exercise price of $1.37 per share, approved earlier in 2026 subject to shareholder approval and the same Form S-8. After these grants, he directly owns 208,132 ordinary shares and holds options for 40,000 shares.
Entera Bio Ltd. reported a grant of stock options to its Chief Financial Officer covering 140,000 ordinary shares at an exercise price of $1.37 per share, expiring on 2036-05-07. The Board approved the grant on May 7, 2026, subject to filing a Registration Statement on Form S-8 for the underlying ordinary shares, which occurred on August 7, 2026. The options vest over three years beginning May 7, 2026, with one third vesting on May 7, 2027 and the remaining two thirds vesting quarterly, subject to full acceleration upon a Change in Control under the company’s 2018 Equity Incentive Plan.
Galitzer Hillel reported acquisition or exercise transactions in this Form 4 filing.
Entera Bio Ltd. granted Chief Operating Officer Hillel Galitzer stock options to buy 200,000 ordinary shares at $1.3700 per share, expiring 2036-05-07. The Board approved the grant on May 7, 2026, contingent on a Form S-8 registration that became effective August 7, 2026. The options vest over three years starting May 7, 2026, with one third vesting on May 7, 2027 and the remaining two-thirds vesting quarterly, subject to full acceleration upon a Change in Control under the Company’s 2018 Equity Incentive Plan.
Entera Bio Ltd. granted its Chief of R&D, Gregory Burshtein, 180,000 stock options to purchase ordinary shares at an exercise price of $1.37 per share. The options expire on May 7, 2036 and vest over three years starting May 7, 2026, with full acceleration upon a Change in Control under the Company’s 2018 Equity Incentive Plan.
Entera Bio Ltd. granted its Chief Executive Officer, Miranda Jayne Toledano, two stock option awards reported as derivative acquisitions on August 7, 2026. One award covers 500,000 ordinary shares at a $1.37 exercise price expiring on May 6, 2036; the other covers 200,000 shares at $2.81 expiring on August 7, 2036.
The 500,000-share grant was approved by the board and shareholders in 2026 and vests over three years beginning May 7, 2026, with one-third vesting on May 7, 2027 and full acceleration upon a Change in Control under the 2018 Equity Incentive Plan. The 200,000-share grant was originally approved in 2022, became effective after a July 2026 financing transaction that funded a Phase 3 trial, and vests over four years starting August 7, 2026, with 25% vesting on the first anniversary and the balance vesting quarterly.
Entera Bio Ltd. director Germano Geno J reported equity compensation. He received 25,014 ordinary shares on August 7, 2026 in lieu of cash director fees for the first two quarters of 2026, raising his direct holdings to 65,014 shares. He was also granted stock options for 50,000 and 43,014 ordinary shares at an exercise price of 1.3700 per share, expiring May 7, 2036 and vesting over one- and three-year schedules starting February 4, 2026, with full acceleration upon a Change in Control under the company’s 2018 Equity Incentive Plan.
Entera Bio Ltd., a clinical-stage developer of oral peptide therapies, reported higher losses as it advanced its lead osteoporosis candidate EB613 and partnered programs EB612 and EB618. For the six months ended June 30, 2026, the company recorded no revenue, research and development expenses of $5.5 million and a net loss of $10.8 million, up from $5.2 million a year earlier, driven by increased development spending and a non-cash remeasurement of pre-funded warrant liabilities.
Cash, cash equivalents and restricted cash totaled $18.5 million at June 30, 2026. In July 2026, Entera completed a private placement raising about $275 million, and the company states that, together with existing cash, this is expected to fund planned operations, including a single Phase 3 EB613 trial in roughly 750 postmenopausal women with osteoporosis and continued advancement of EB612 and EB618 with OPKO, into 2030.